ALL-IMMUNE Late-Effects Study

ALL-IMMUNE Late-Effects Study

We are looking for survivors of Acute Lymphoblastic Leukaemia (ALL) and their household members for our research study on gut bacteria.

Researchers at SAHMRI and SA Health are running a project funded by the Leukaemia Foundation called the ALL-IMMUNE late-effects Study. The aim of this study is to study the gut bacteria of Acute Lymphoblastic Leukaemia (ALL) survivors and assess its role on the long-term health of ALL survivors.

What is the research for?

Survivors of blood cancers such as Acute Lymphoblastic Leukaemia (ALL) are at greater risk of developing health issues (called late-effects) later in life. We suspect that persistent changes in gut bacteria may contribute to this. We will study the gut bacteria of ALL survivors compared to siblings or other household members who have not had ALL to assess this.

Who can participate?

  • Survivors of ALL who have completed their treatment in the last 10 years.
  • Siblings or members of their household.

What is involved?

After completing our online eligibility form and consent to be contacted, you will receive a copy of the participant information and consent form (PICF) which will provide further study details. You will then be contacted by phone so that you have the opportunity discuss the research and address your concerns. During this time, you will also be asked to provide your consent to participate. If you consent to participate, we will mail a stool (poo) sample collection kit to collect a stool sample at home which you are able to drop off at any local SA Pathology. We only need a single sample from both the ALL survivor and household member for our study. We will also and send you a secured link to with a health questionnaire which will ask you a few questions related to your basic medical history and medication use.

Check your eligibility and register for the study here

Get involved!

If you would like to speak to our study coordinator, please email late.effects@sahmri.com. This research study has been approved by the Women’s and Children’s Health Network Human Research Ethics Committee, Protocol number: 2022/HRE00198.

This project is funded by the Leukaemia Foundation and the Cancer Council